摘要
目的观察精骨补肾颗粒(黄精、骨碎补、桑葚等)对糖皮质激素性骨质疏松症(glucocorticoid induced osteoporosis,GIOP)大鼠的骨密度(BMD)、抗酒石酸酸性磷酸酶(TRAP)、碱性磷酸酶(ALP)、肌钙蛋白(Tn)、血清降钙素(CT)、雌二醇(E2)的影响及可能的作用机制。方法将72只雌性大鼠随机分为正常对照组,模型对照组,阳性对照组(仙灵骨葆胶囊),精骨补肾颗粒低、中、高剂量组。除正常对照组外,其余各组大鼠每周2次肌肉注射地塞米松2.5 mg/kg,同时每日灌胃给药连续9周。实验结束后眼球取血,用酶联免疫法测定大鼠Tn、TRAP、ALP、CT、E2指标,用双能X线骨密度仪对大鼠离体股骨上1/3 BMD进行检测。结果 GIOP大鼠对照组的TRAP、ALP明显升高,BMD、Tn、CT、E2明显降低,与正常对照组比较,有显著性差异(P<0.01);精骨补肾颗粒低、中、高剂量组可显著降低GIOP大鼠TRAP、ALP含有量,显著升高BMD、Tn、CT、E2值,且存在一定的剂量依赖关系,与模型对照组比较有显著性差异(P<0.05或P<0.01)。结论精骨补肾颗粒对骨质疏松症大鼠具有一定的治疗作用。
AIM To study the effects of Jinggu Bushen Granules（Polygonati Rhizoma,Drynariae Rhizoma,Mori Fructu,etc.） on glucocorticoid induced osteoporosis（GIOP） in rat bone mineral density（BMD）,tartrate resistant acid phosphatase（TRAP）,alkaline phosphatase（ALP）,troponin（Tn）,calcitonin（CT）,estradiol（E2）,and to explore the mechanism of it preventing and treating osteoporosis to serve an experimental basis for clinical applications.METHODS Seventy-two Wistar-Kyoto strain rats were randomly divided into six groups：normal group,control group,positive group with Xianling Gubao Capsules,experimental groups with Jinggu Bushen Granules low-,medium-and high-dose.Except for the normal group,all of the groups were injected with dexamethasone for two weeks and fed respectively with corresponding medicines for nine weeks.After the last administration,rats＇ eyeballs were picked up to obtain blood.The assay of Tn,TRAP,ALP,CT and E2 in serum were measured by ELISA;in vitro the BMD proximal one third of the femur was determined by dual-energy X-ray absorptiometry.RESULTS In GIOP model group,the contents of TRAP,ALP increased and BMD,Tn,CT,E2 reduced with significant differences compared to those of the normal group（P〈0.01）.In three experimental groups,the contents of TRAP,ALP reduced and the BMD,Tn,CT,E2 increased.There were significant differences compared to the model group（P〈0.05 or P〈0.01）.CONCLUSIONS The experimental results have suggested that Jinggu Bushen Granules have certain protective effects against GIOP rats.
出处
《中成药》
CAS
CSCD
北大核心
2016年第6期1221-1225,共5页
Chinese Traditional Patent Medicine
基金
安徽省卫生厅中医药管理局科研计划(2014XY39)
